Literature DB >> 26347011

[Spincter preservation after selective chemoradiotherapy of rectal cancer. Interim results of the OCUM study].

J Baral1, M R Schön1, R Ruppert2, H Ptok3, J Strassburg4, P Brosi5, M E Kreis6, A Lewin7, J Sauer8, S Sawicki9, L Schiffmann10, G Winde11, T Junginger12, S Merkel13, P Hermanek13.   

Abstract

BACKGROUND: In a prospective multicenter observational study (OCUM) neoadjuvant chemoradiotherapy (nRCT) was selectively administered depending on the risk of local recurrence and based on the distance between tumor and mesorectal fascia in pretherapeutic high-resolution magnetic resonance imaging (MRI).
OBJECTIVE: Frequency and quality of abdominoperineal excision (APE) and sphincter preserving operations. PATIENTS AND METHODS: Of 642 patients treated in 13 hospitals 389 received surgery alone and 253 nRCT followed by surgery. By univariate and multivariate analysis risk factors for APE were determined. Quality parameters were the quality grade of mesorectal excision, the pathohistological involvement of the circumferential resection margin and intraoperative local dissemination of tumor cells. RESULTS AND DISCUSSION: In 12.8 % of the patients APE was performed. Independent risk factors for APE were tumor location in the lower third of the rectum and the individual hospitals, where APE varied between 0 and 32 %. This variation was chiefly caused by the different case mix. Hospitals with a high APE rate (> 30 %) treated significantly more patients with very low lying carcinomas (< 3 cm above the anal verge) and more advanced tumors. The median height of the tumor in cases of APE was nearly equal in all participating hospitals. Independent on the number of cases the quality of rectal surgery was high. Within the patient groups of primary surgery and nRCT the oncological quality parameter did not significantly differ between sphincter preservation and APE. As far as sphincter preservation is concerned the results justify a selective application of nRCT in patients with rectal carcinoma. The long-term results still have to be awaited.

Entities:  

Keywords:  Abdominoperineal resection; Neoadjuvant chemoradiotherapy; OCUM study; Rectal carcinoma; Sphincter preservation

Mesh:

Year:  2015        PMID: 26347011     DOI: 10.1007/s00104-015-0083-z

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  23 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

Review 2.  What is the role for the circumferential margin in the modern treatment of rectal cancer?

Authors:  Iris D Nagtegaal; Phil Quirke
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

3.  Neoadjuvant radiotherapy for rectal cancer: meta-analysis of randomized controlled trials.

Authors:  Nuh N Rahbari; Heike Elbers; Vasileios Askoxylakis; Edith Motschall; Ulrich Bork; Markus W Büchler; Jürgen Weitz; Moritz Koch
Journal:  Ann Surg Oncol       Date:  2013-09-04       Impact factor: 5.344

4.  Low rectal cancer: a call for a change of approach in abdominoperineal resection.

Authors:  Iris D Nagtegaal; Cornelius J H van de Velde; Corrie A M Marijnen; Jan H J M van Krieken; Philip Quirke
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

5.  The prediction of local recurrence in rectal adenocarcinoma by histopathological examination.

Authors:  P Quirke; M F Dixon
Journal:  Int J Colorectal Dis       Date:  1988-06       Impact factor: 2.571

6.  [Quality indicators of diagnosis and therapy in MRI-based neoadjuvant radiochemotherapy for rectal cancer - interim analysis of a Prospective Multicentre Observational Study (OCUM)].

Authors:  R Ruppert; H Ptok; J Strassburg; C A Maurer; T Junginger; S Merkel; P Hermanek
Journal:  Zentralbl Chir       Date:  2012-06-14       Impact factor: 0.942

Review 7.  Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer.

Authors:  Laura De Caluwé; Yves Van Nieuwenhove; Wim P Ceelen
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

8.  Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma.

Authors:  Christopher H Crane; John M Skibber; Barry W Feig; Jean-Nicolas Vauthey; Howard D Thames; Steve A Curley; Miguel A Rodriguez-Bigas; Robert A Wolff; Lee M Ellis; Marc E Delclos; Edward H Lin; Nora A Janjan
Journal:  Cancer       Date:  2003-01-15       Impact factor: 6.860

Review 9.  Controversies in abdominoperineal excision.

Authors:  Torbjörn Holm
Journal:  Surg Oncol Clin N Am       Date:  2014-01       Impact factor: 3.495

10.  Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.

Authors:  David Sebag-Montefiore; Richard J Stephens; Robert Steele; John Monson; Robert Grieve; Subhash Khanna; Phil Quirke; Jean Couture; Catherine de Metz; Arthur Sun Myint; Eric Bessell; Gareth Griffiths; Lindsay C Thompson; Mahesh Parmar
Journal:  Lancet       Date:  2009-03-07       Impact factor: 79.321

View more
  2 in total

1.  Can Pre-Treatment Inflammatory Parameters Predict the Probability of Sphincter-Preserving Surgery in Patients with Locally Advanced Low-Lying Rectal Cancer?

Authors:  Richard Partl; Katarzyna Lukasiak; Bettina Stranz; Eva Hassler; Marton Magyar; Heidi Stranzl-Lawatsch; Tanja Langsenlehner
Journal:  Diagnostics (Basel)       Date:  2021-05-25

2.  Clinical parameters predictive for sphincter-preserving surgery and prognostic outcome in patients with locally advanced low rectal cancer.

Authors:  Richard Partl; Marton Magyar; Eva Hassler; Tanja Langsenlehner; Karin Sigrid Kapp
Journal:  Radiat Oncol       Date:  2020-05-06       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.